Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 2/20 | 0.45 |
| ▸ | MMP1 | P03956 | 2/20 | 0.41 |
| ▸ | MMP9 | P14780 | 2/20 | 0.41 |
| ▸ | MMP13 | P45452 | 2/20 | 0.41 |
| ▸ | MMP3 | P08254 | 1/20 | 0.41 |
| ▸ | MMP7 | P09237 | 1/20 | 0.41 |
| ▸ | ALOX5AP | P20292 | 2/20 | 0.40 |
| ▸ | FEN1 | P39748 | 2/20 | 0.40 |
| ▸ | F10 | P00742 | 9/20 | 0.40 |
| ▸ | HTR6 | P50406 | 2/20 | 0.39 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 2/20 | 0.37 |
| ▸ | CA2 | P00918 | 2/20 | 0.37 |
| ▸ | CA4 | P22748 | 2/20 | 0.37 |
| ▸ | CA9 | Q16790 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1618700 | 0.88 | PKM (0.60) | PKMALOX5APFEN1HTR6 | |
| SCHEMBL14538037 | 0.78 | ALDH1A1 (0.46) | PKMMMP1MMP9MMP13MMP3 | |
| SCHEMBL16430559 | 0.77 | ALOX5AP (0.48) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL2266915 | 0.77 | PKM (0.73) | PKMF10 | |
| Hydrochloric Acid SCHEMBL5733824 | 0.76 | PKM (0.71) | PKMF10 | |
| SCHEMBL14325344 | 0.76 | HSD11B1 (0.46) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL734974 | 0.75 | HSD11B1 (0.48) | MMP1MMP9MMP13MMP3MMP7 | |
| SCHEMBL6184463 | 0.74 | PKM (0.54) | PKMCA1CA2CA4CA9 | |
| SCHEMBL1661410 | 0.74 | PKM (0.53) | PKMHTR6 | |
| SCHEMBL15915927 | 0.73 | ALOX5AP (0.52) | ALOX5APFEN1HTR6CA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6936610-B2 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2005-08-30 | — | — | US | disclosed |
| EP-0937048-B1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ASTRAZENECA AB (SE) | 2004-01-21 | — | — | EP | disclosed |
| EP-1358909-A1 | Heteroaryl-phenyl derivatives as factor xa inhibitors for use as antithrombotic and anticoagulant agents | AstraZeneca AB (SE) | 2003-11-05 | — | — | EP | disclosed |
| US-20030195203-A1 | Heterocyclic derivatives | ASTRAZENECA UK LIMITED (GB) | 2003-10-16 | — | — | US | disclosed |
| US-6300330-B1 | BLOOD COAGULATION FACTOR X INHIBITORS AS ANTICOAGULANTS | ZENECA LIMITED (GB) | 2001-10-09 | — | — | US | disclosed |
| EP-0937048-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1999-08-25 | — | — | EP | disclosed |
| WO-1998021188-A1 | HETEROCYCLE DERIVATIVES WHICH INHIBIT FACTOR Xa | ZENECA LIMITED (GB) | 1998-05-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195203-A1 | Heterocyclic derivatives | F12, F11, F2 | PKM 3921/4885MMP1 2789/4885MMP9 3975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.